Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innate PharmaIPHA -1.39%41 Earnings Yield (Joel Greenblatt) % is -35.21% as of Dec. 2025. GuruFocus rates IPHA with a GF Score™ of 41/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,334 Biotechnology companies, Innate Pharma ranks worse than 75.19% on this metric.
Innate Pharma's Enterprise Value for the quarter that ended in Dec. 2025 was $150.23 Mil.
Innate Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-56.70 Mil. Innate Pharma's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was -35.21%.
The historical rank and industry rank for Innate Pharma's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
IPHA'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -67.96 Med: -6.08 Max: 149.5
Current: -37.04
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Innate Pharma was 149.50%. The lowest was -67.96%. And the median was -6.08%.
IPHA's Earnings Yield (Joel Greenblatt) % is ranked worse than 75.19% of 1334
companies
in the Biotechnology industry
Industry Median: -9.94
vs IPHA: -37.04
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Innate Pharma's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Innate Pharma Earnings Yield (Joel Greenblatt) % Related Terms
Innate Pharma Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Innate Pharma's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innate Pharma's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Innate Pharma's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Innate Pharmas Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of -35.21% mean?
Innate Pharma (IPHA) has a Earnings Yield (Joel Greenblatt) % of -35.21% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Innate Pharma and its competitors. According to the industry distribution chart, Innate Pharma ranks #1003 out of 1334 companies in the Biotechnology industry, placing it in the top 75.2%.
Is Innate Pharma's Earnings Yield (Joel Greenblatt) % too high?
Innate Pharma's current Earnings Yield (Joel Greenblatt) % is -35.21%. Based on the distribution chart, Innate Pharma ranks #1003 out of 1334 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #1003 out of 1334 companies for Earnings Yield (Joel Greenblatt) %. This places Innate Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Innate Pharma and its competitors. Innate Pharma's current Earnings Yield (Joel Greenblatt) % is -35.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.78 — trading 1009.4% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -35.21%. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Earnings Yield (Joel Greenblatt) % is -35.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.78 is trading 1009.4% above its estimated GF Value™ of $0.16.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
Earnings Yield (Joel Greenblatt) %: -35.21%
GF Value™: $0.16 vs. price of $1.78 (1009.4% above fair value)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score
Get the complete analysis for IPHA
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
